Abstract
Endocannabinoids are lipid-based retrograde neurotransmitters that bind to cannabinoid receptors, two of which are currently described: CB1 and CB2. The two main active components of cannabis are tetrahydrocannabinol (THC) and cannabidiol (CBD), have differing binding affinities to the receptors, allowing them to mediate different systemic effects as well as modulate each other's effects. Due to these varied properties, the therapeutic effect of marijuana is directly correlated with the THC:CBD ratio in a particular formulation. Current FDA-approved synthetic and cannabis-derived products are indicated for the treatment of nausea induced by chemotherapy, seizure disorders, and anorexia in AIDS patients. Regarding the treatment of chronic neuropathic pain and cancer pain, research has shown a low-to moderate quality evidence for use of cannabinoids, but greatly promising in providing alternatives to opioids. Challenges in medical research on cannabis remain, particularly in terms of inconsistent chemical composition and sourcing, small sample sizes, poor controls, and short duration of trials. Major medical institutions call for more thorough research and further investigation of marijuana safety and efficacy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
